FDA-Industry GDUFA Reauthorization Meeting July 29, 2021, 10:00 am – 11:45 am Virtual Meeting

Purpose

To continue negotiations to reauthorize GDUFA (GDUFA III).

Participants

	<u>Industry</u>	
CDER	John DiLoreto	BPTF
OC/OCC	David Gaugh	AAM
CDER	Kiran Krishnan	AAM (Apotex)
OC/OCC		
CDER	Brian McCormick	AAM (Teva)
ORA	Lisa Parks	AAM
CDER	Gil Roth	PBOA
CDER	Molly Ventrelli	AAM (Fresenius-Kabi)
CDER		
CDER		
	OC/OCC CDER OC/OCC CDER ORA CDER CDER CDER	CDER John DiLoreto OC/OCC David Gaugh CDER Kiran Krishnan OC/OCC CDER Brian McCormick ORA Lisa Parks CDER Gil Roth CDER Molly Ventrelli CDER

FDA Supporting Staff

Tiana Barnes, Dat Doan, and Tawni Schwemer

Discussion

FDA acknowledged that FDA and Industry have come to an initial agreement regarding allocation of revenues among fee categories and will continue to work toward an initial overall agreement as well as an initial agreement on the Commitment Letter.

FDA and Industry met to discuss the draft Commitment Letter.

Next Meeting

If needed, FDA and Industry may meet again to make further revisions to the draft Commitment Letter. Any further meeting(s) are to be determined.